HPB P51 The impact of the SARS-CoV-2 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study

Abstract Background The SARS-CoV-2 pandemic has had an unprecedented impact on healthcare systems, and cancer patients were amongst the most vulnerable. CONTACT is a national multidisciplinary study assessing of upon diagnostic treatment pathways among with pancreatic ductal adenocarcinoma (PDAC). Methods A novel, mixed prospective retrospective design, case identification both cohorts, trainee-performed data collection. consecutive newly diagnosed PDAC from pre-COVID cohort (07/01/2019–03/03/2019) compared to during first wave in UK (‘COVID’ cohort, 16/03/2020–10/05/2020), 12-month follow-up. Results Among 984 (pre-COVID: n=483, COVID: n=501), across 96 hospitals, COVID less likely receive staging investigations other than CT scan (148/501, 29.5% vs 180/486, 37.2%; p=0.01). treated curative intent, there was reduction proportion recommended surgery (42/77, 54.5% 72/94, 76.6%, p=0.001) increase neoadjuvant therapy (35/77, 45.5% 22/94, 23.4%, p=0.002). within non-curative pathway, fewer (201/424, 47.4% 223/389, 57.3%, p=0.004) or received palliative (87/424, 20.5% 103/389, 26.5%, p=0.045). Ultimately, underwent resection (29/501, 6.4% 45/483, 9.3%, OR 0.64, 95%CI: 0.37–0.97, p=0.036), whilst more no whatsoever (347/501, 69.3% 286/483, 59.2% p=0.009). There difference median survival between (105 days, IQR: 86–124 130 108–157, p=0.093). Conclusions confirms alarming provided pandemic. Restoration services pre-pandemic standards must be urgently addressed.